Evidence map›Paper›PMID 33535408›Full record

ArticleBiomedicines2021

A Strategy to Elicit M2e-Specific Antibodies Using a Recombinant H7N9 Live Attenuated Influenza Vaccine Expressing Multiple M2e Tandem Repeats.

Daria Mezhenskaya, Irina Isakova-Sivak, Tatiana Kotomina, Victoria Matyushenko, Min-Chul Kim, Noopur Bhatnagar, Ki-Hye Kim, Sang-Moo Kang, Larisa Rudenko

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Daria MezhenskayaDepartment of Virology, Institute of Experimental Medicine, 197376 Saint Petersburg, Russia.ORCID 0000-0001-6922-7682
Irina Isakova-SivakDepartment of Virology, Institute of Experimental Medicine, 197376 Saint Petersburg, Russia.
Tatiana KotominaDepartment of Virology, Institute of Experimental Medicine, 197376 Saint Petersburg, Russia.
Victoria MatyushenkoDepartment of Virology, Institute of Experimental Medicine, 197376 Saint Petersburg, Russia.
Min-Chul KimCenter for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.
Noopur BhatnagarCenter for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.
Ki-Hye KimCenter for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.
Sang-Moo KangCenter for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.ORCID 0000-0001-6198-331X
Larisa RudenkoDepartment of Virology, Institute of Experimental Medicine, 197376 Saint Petersburg, Russia.
Institute of Experimental Medicine · RUGeorgia State University · US

Funding

Influenza vaccines inducing broadly cross protective immunityR01AI093772 · NIAID · GEORGIA STATE UNIVERSITY · PI KANG, SANG-MOO · 2011 to 2020
$4.2M
NIAID NIH HHS R01 AI093772NIH HHS AI1093772, AI147042
6 · The paper itself

Abstract

Influenza viruses remain a serious public health problem. Vaccination is the most effective way to prevent the disease; however, seasonal influenza vaccines demonstrate low or no effectiveness against antigenically drifted and newly emerged influenza viruses. Different strategies of eliciting immune responses against conserved parts of various influenza virus proteins are being developed worldwide. We constructed a universal live attenuated influenza vaccine (LAIV) candidate with enhanced breadth of protection by modifying H7N9 LAIV by incorporating four epitopes of M2 protein extracellular part into its hemagglutinin molecule. The new recombinant H7N9+4M2e vaccine induced anti-M2e antibody responses and demonstrated increased protection against heterosubtypic challenge viruses in direct and serum passive protection studies, compared to the classical H7N9 LAIV. The results of our study suggest that the H7N9+4M2e warrants further investigation in pre-clinical and phase 1 clinical trials.

Indexed as

ADCCCDCcross-protectionIgGinfluenzalive attenuated influenza vaccineM2e antigenmouse modelrecombinant influenza virusuniversal influenza vaccine

Identifiers

PMID33535408
PMCPMC7912525
OpenAlexW3129097614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.